Prognostic significance of mucins in colorectal cancer with different DNA mismatch-repair status

Background: Expression of mucin antigen MUC1 and down regulation of MUC2 are associated with adverse prognosis in colorectal cancer (CRC), but their prognostic significance with respect to differing DNA mis- match repair (MMR) status is poorly understood. Objective: To determine the prognostic significance of MUC1 and MUC2 in CRC with different MMR statuses. Methods: Using the tissue microarray (TMA) technique, a series of 1420 unselected, non-consecutive CRC resections was subdivided into three groups: (1) MMR-proficient; (2) MLH1-negative; and (3) presumed hereditary non-polyposis colon cancer (HNPCC). Immunohistochemical analysis of MUC1 and MUC2 expression (>0%) and loss (0%) was performed, and the results were correlated with clinicopathological parameters. Results: In MMR-proficient CRC, MUC1 expression was more frequently found in tumours with higher tumour stage (p = 0.004) and higher tumour grade (p = 0.041) and loss of MUC2 was associated with higher tumour stage (p = 0.028), node stage (p = 0.001), presence of vascular invasion (p = 0.028) and worse survival (p = 0.034). In MLH1-negative CRC, MUC2 loss was associated with the presence of lymph node metastasis (p = 0.028) and worse survival (p = 0.015), but there was no association between MUC1 expression and clinicopathological features. In presumed HNPCC, MUC1 expression and MUC2 loss were not associated with clinicopathological parameters. Conclusions: Mucins have a prognostic significance in sporadic CRC, but not in hereditary CRC. Loss of MUC2 is an adverse prognostic factor in MMR-proficient and MLH1-negative CRC, whereas MUC1 expression is associated with tumour progression in MMR-proficient CRC only.

[1]  J. Jass,et al.  Role of the mitogen-activated protein kinase and phosphoinositide 3-kinase/AKT pathways downstream molecules, phosphorylated extracellular signal-regulated kinase, and phosphorylated AKT in colorectal cancer-a tissue microarray-based approach. , 2006, Human pathology.

[2]  D. Borghys,et al.  A new approach to the validation of tissue microarrays , 2006, The Journal of pathology.

[3]  J. Jass Re: Ward et al. Routine testing for mismatch repair deficiency in sporadic colorectal cancer is justified. J Pathol 2005;207:377–384 , 2006, The Journal of pathology.

[4]  R. Ward,et al.  Routine testing for mismatch repair deficiency in sporadic colorectal cancer is justified , 2005, The Journal of pathology.

[5]  A. Hölscher,et al.  MUC1 and Nuclear β-Catenin Are Coexpressed at the Invasion Front of Colorectal Carcinomas and Are Both Correlated with Tumor Prognosis , 2004, Clinical Cancer Research.

[6]  Ronald Simon,et al.  Tissue microarrays in drug discovery , 2003, Nature Reviews Drug Discovery.

[7]  A. Hölscher,et al.  Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl‐Lewisa and sialyl‐Lewisx antigens in colorectal adenocarcinoma , 2002, Histopathology.

[8]  H. Moch,et al.  Tissue microarrays for rapid linking of molecular changes to clinical endpoints. , 2001, The American journal of pathology.

[9]  H. Moch,et al.  Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. , 2001, Journal of the National Cancer Institute.

[10]  Holger Moch,et al.  Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade , 2001, The Journal of pathology.

[11]  J. Jass,et al.  Mucin core proteins as differentiation markers in the gastrointestinal tract , 2000, Histopathology.

[12]  H. Weiss,et al.  Racial differences in the prognostic usefulness of MUC1 and MUC2 in colorectal adenocarcinomas. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  Y. Chen,et al.  Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. , 2000, Journal of the National Cancer Institute.

[14]  J. Palazzo,et al.  Neoplastic progression occurs through mutator pathways in hyperplastic polyposis of the colorectum , 2000, Gut.

[15]  B. Leggett,et al.  Mucin core protein expression in colorectal cancers with high levels of microsatellite instability indicates a novel pathway of morphogenesis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  Y. Ajioka,et al.  Clinical significance of MUC1 and MUC2 mucin and p53 protein expression in colorectal carcinoma. , 2000, Japanese journal of clinical oncology.

[17]  B. Leggett,et al.  Immunohistochemical Staining Patterns of MUC1, MUC2, MUC4, and MUC5AC Mucins in Hyperplastic Polyps, Serrated Adenomas, and Traditional Adenomas of the Colorectum , 1999, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[18]  B. Leggett,et al.  Ultrastructural Localization of Epithelial Mucin Core Proteins in Colorectal Tissues , 1999, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[19]  H. Moch,et al.  High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. , 1999, The American journal of pathology.

[20]  N. Kohno,et al.  MUC-1 expression as a predictor of the curative endoscopic treatment of submucosally invasive colorectal carcinoma , 1998, Diseases of the colon and rectum.

[21]  B. Longenecker,et al.  The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy. , 1998, Molecular medicine today.

[22]  N. Kohno,et al.  Immunoreactive MUC1 Expression at the Deepest Invasive Portion Correlates with Prognosis of Colorectal Cancer , 1998, Oncology.

[23]  K. Do,et al.  Morphology of sporadic colorectal cancer with DNA replication errors , 1998, Gut.

[24]  S. Baldus,et al.  Coexpression of MUC1 mucin peptide core and the thomsen‐friedenreich antigen in colorectal neoplasms , 1998, Cancer.

[25]  F. Vitelli,et al.  Microsatellite instability in sporadic mucinous colorectal carcinomas: relationship to clinico‐pathological variables , 1997, The Journal of pathology.

[26]  J. Jass,et al.  MUC1 and MUC2 mucins in flat and polypoid colorectal adenomas. , 1997, Journal of clinical pathology.

[27]  J. Jass,et al.  Significance of MUC1 and MUC2 mucin expression in colorectal cancer. , 1996, Journal of clinical pathology.

[28]  A. Sonnenberg,et al.  Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components , 1995, The Journal of cell biology.

[29]  O. Elroy-Stein,et al.  Tyrosine phosphorylation of the MUC1 breast cancer membrane proteins Cytokine receptor‐like molecules , 1994, FEBS letters.

[30]  H. Stein,et al.  Expression of MUC2‐mucin in colorectal adenomas and carcinomas of different histological types , 1994, International journal of cancer.

[31]  B. Vogelstein,et al.  Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. , 1994, The American journal of pathology.

[32]  F. Real,et al.  Differential apomucin expression in normal and neoplastic human gastrointestinal tissues. , 1994, Gastroenterology.

[33]  D. Ota,et al.  MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. , 1994, Gastroenterology.

[34]  L. Aaltonen,et al.  Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. , 1993, Cancer research.

[35]  D. Kufe,et al.  Localization of tumor‐associated glycoprotein DF3 in normal, inflammatory, and neoplastic lesions of the colon , 1993, Cancer.

[36]  R. Dahiya,et al.  Heterogeneity of mucin gene expression in normal and neoplastic tissues. , 1993, Cancer research.

[37]  S. Itzkowitz,et al.  Mucin gene expression in colonic tissues and cell lines. , 1992, Cancer research.

[38]  R. Dahiya,et al.  Mucin production by human colonic carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastasis. , 1991, The Journal of clinical investigation.

[39]  S. Povey,et al.  The hypervariable gene locus PUM, which codes for the tumour associated epithelial mucins, is located on chromosome 1, within the region 1g21–24 , 1987, Annals of human genetics.

[40]  J. Taylor‐Papadimitriou,et al.  The human tumour-associated epithelial mucins are coded by an expressed hypervariable gene locus PUM , 1987, Nature.

[41]  T. Irimura,et al.  Expression of MUC1 recognized by monoclonal antibody MY.1E12 is a useful biomarker for tumor aggressiveness of advanced colon carcinoma , 2004, Clinical & Experimental Metastasis.

[42]  諏訪 高麿 Increased invasiveness of MUC1 cDNA-transfected human gastric cancer MKN74 cells , 1998 .

[43]  P. Schlag,et al.  Immunodetection of epithelial mucin (MUC1, MUC3) and mucin-associated glycotopes (TF, Tn, and sialosyl-Tn) in benign and malignant lesions of colonic epithelium: apolar localization corresponds to malignant transformation , 1997, Virchows Archiv.

[44]  Kim Ys,et al.  Altered mucin core peptide immunoreactivity in the colon polyp-carcinoma sequence. , 1996 .

[45]  M. Copin,et al.  Aberrant expression of a human mucin gene (MUC5AC) in rectosigmoid villous adenoma. , 1996, Gastroenterology.

[46]  Y. Kim,et al.  Altered mucin core peptide immunoreactivity in the colon polyp-carcinoma sequence. , 1996, Oncology research.

[47]  S. Gendler,et al.  Epithelial mucin genes. , 1995, Annual review of physiology.